Pareto on Calliditas today
Pareto research Today on Calliditas:
- …Novartis drug Atrasentan seems to show no effect in our view at week 36….
- …Calliditas’ Nefecon (Tarpeyo/Kinpeygo) will remain the ONLY safe and effective treatment available…
In my veiw - Very Bullish for Calliditas. Takeover candidate in next months.
Two important catalysts in Q4:
- full US approval (Calliditas is now selling based on preliminary apporval, that limits how the drug can be marketed)
- China appoval - very important - IgA nephropathy is very common disease in China, much more common vs Europe
Summary of Carnegie research on Calliditas
https://fitinvestmentideas.com/2023/10/20/carnegie-on-calliditas-us-and-china-approvals-due-in-q4/
- …Novartis drug Atrasentan seems to show no effect in our view at week 36….
- …Calliditas’ Nefecon (Tarpeyo/Kinpeygo) will remain the ONLY safe and effective treatment available…
In my veiw - Very Bullish for Calliditas. Takeover candidate in next months.
Two important catalysts in Q4:
- full US approval (Calliditas is now selling based on preliminary apporval, that limits how the drug can be marketed)
- China appoval - very important - IgA nephropathy is very common disease in China, much more common vs Europe
Summary of Carnegie research on Calliditas
https://fitinvestmentideas.com/2023/10/20/carnegie-on-calliditas-us-and-china-approvals-due-in-q4/
NordicGuy
08.11.2023 kl 12:44
890
Very positive research on Calliditas by Redeye:
Improved conversion rate ahead of a new Tarpeyo label
Tarpeyo is gradually improving the patient conversion rate
During the 2023 Tarpeyo’s conversion rate has improved gradually from low
levels. Calliditas maintains the full year sales guide despite reporting slightly soft
Q3 sales and points to improved activity in late Q3 and early Q4. Our take is that
this is another sign of improved conversion ahead of the PDUFA date on 20th
December. Our updated view is a base case valuation of SEK 280 (295) and a
Bull Case of SEK 415 (445) and a Bear Case of SEK 70 (75)
Free access:
https://www.redeye.se/api/articles/download-file/419108b5-b484-3c5f-af86-5621e0481459
Improved conversion rate ahead of a new Tarpeyo label
Tarpeyo is gradually improving the patient conversion rate
During the 2023 Tarpeyo’s conversion rate has improved gradually from low
levels. Calliditas maintains the full year sales guide despite reporting slightly soft
Q3 sales and points to improved activity in late Q3 and early Q4. Our take is that
this is another sign of improved conversion ahead of the PDUFA date on 20th
December. Our updated view is a base case valuation of SEK 280 (295) and a
Bull Case of SEK 415 (445) and a Bear Case of SEK 70 (75)
Free access:
https://www.redeye.se/api/articles/download-file/419108b5-b484-3c5f-af86-5621e0481459
NordicGuy
13.11.2023 kl 17:08
826
DNB on Callitidas today:
Set for improved conversion rate ahead of Tarpeyo label
Tarpeyo will enjoy 2–4 years without any competitive eGFR result– we believe Novartis is probably best placed in terms of a future competitive IgAN challenger, eventually.
Calliditas Therapeutics (Calliditas) reiterated its full-year sales guidance despite reporting slightly soft Q3 sales, pointing to increased activity in late-Q3/early-Q4; we believe this is another sign of an improved conversion rate ahead of the PDUFA date (20 December).
We reiterate our fair value range of SEK265–315, but have lowered our bull-case value to SEK415 (445) and our and bear-case value to SEK70 (75).
Set for improved conversion rate ahead of Tarpeyo label
Tarpeyo will enjoy 2–4 years without any competitive eGFR result– we believe Novartis is probably best placed in terms of a future competitive IgAN challenger, eventually.
Calliditas Therapeutics (Calliditas) reiterated its full-year sales guidance despite reporting slightly soft Q3 sales, pointing to increased activity in late-Q3/early-Q4; we believe this is another sign of an improved conversion rate ahead of the PDUFA date (20 December).
We reiterate our fair value range of SEK265–315, but have lowered our bull-case value to SEK415 (445) and our and bear-case value to SEK70 (75).
NordicGuy
24.11.2023 kl 08:48
727
Calliditas Announced Today: Nefecon receives market approval in China
Calliditas' China partner, Everest Medicines, today announced that Nefecon has received market approval from the Chinese regulatory agency NMPA for the treatment of IgAN. China has the highest prevalence of IgAN with an estimated five million patients.
IgAN is common disease in China, while in the west it is consdered a rare disease. When I spoke to the company on this six months ago, the management was very bullish on China opportunity.
Calliditas' China partner, Everest Medicines, today announced that Nefecon has received market approval from the Chinese regulatory agency NMPA for the treatment of IgAN. China has the highest prevalence of IgAN with an estimated five million patients.
IgAN is common disease in China, while in the west it is consdered a rare disease. When I spoke to the company on this six months ago, the management was very bullish on China opportunity.
NordicGuy
13.12.2023 kl 13:30
602
FDA approval deadline is next week. Calliditas has already had the preliminary approval for about a year. Final approval is very likely according to the analysts I talked to this week. Big catalyst for Calliditas next week!
The full FDA approval means that Calliditas will be able to market its drug publicly.
The full FDA approval means that Calliditas will be able to market its drug publicly.
NordicGuy
13.12.2023 kl 16:45
562
Callitidas is today up 5%.
My guess is that before FDA approval next week, the stock could reach 120 SEK.
After the FDA approval, we may see all time high. 140-150?
any views?
My guess is that before FDA approval next week, the stock could reach 120 SEK.
After the FDA approval, we may see all time high. 140-150?
any views?
NordicGuy
14.12.2023 kl 10:29
515
Calliditas at 106. My next week target is 120, FDA approval deadline is 20 December.
NordicGuy
22.12.2023 kl 15:06
421
When CALTX was around 100, I was saying it would reach 120 before the approval and 150 after the approval.
It was 110 before he approval and is 135 two days after. It will breach 140 next week.
Below is today's interview with Callitidas CEO:
https://www.redeye.se/research/968342/calliditas-interview-with-ceo-renee-aguiar-lucander-2?utm_source=MB&utm_medium=email
It was 110 before he approval and is 135 two days after. It will breach 140 next week.
Below is today's interview with Callitidas CEO:
https://www.redeye.se/research/968342/calliditas-interview-with-ceo-renee-aguiar-lucander-2?utm_source=MB&utm_medium=email